CLORPRES® is a combination of clonidine hydrochloride (a centrally acting antihypertensive agent) and chlorthalidone (a diuretic). CLORPRES® is available as tablets for oral administration in three dosage strengths: 0.1 mg/15 mg, 0.2 mg/15 mg and 0.3 mg/15 mg of clonidine hydrochloride/chlorthalidone, respectively.
The inactive ingredients are ammonium chloride, colloidal silicon dioxide, croscarmellose sodium (Type A), magnesium stearate, microcrystalline cellulose, sodium lauryl sulfate, D&C yellow #10.
CLORPRES® (clonidine hydrochloride USP/chlorthalidone USP) is indicated in the treatment of hypertension. This fixed combination drug is not indicated for initial therapy of hypertension. Hypertension requires therapy titrated to the individual patient. If the fixed combination represents the dosage so determined, its use may be more convenient in patient management. The treatment of hypertension is not static, but must be reevaluated as conditions in each patient warrant.
Media Articles Related to Clorpres (Clonidine / Chlorthalidone)
Renal Denervation for Uncontrolled Hypertension
Source: Medscape Critical Care Headlines [2017.03.20]
Is renal denervation an effective option for managing uncontrolled hypertension?
Current Opinion in Nephrology and Hypertension
New role for immune cells in preventing diabetes and hypertension
Source: Diabetes News From Medical News Today [2017.03.20]
Immune cells which are reduced in number by obesity could be a new target to treat diseases such as type 2 diabetes and hypertension that affect overweight people, according to a collaborative...
Study reveals link between hypertension and brain changes in rats
Source: Hypertension News From Medical News Today [2017.03.10]
New research investigates the changes in brain activity and arterial blood flow that occur with the onset of hypertension in rats.
Evidence review supports pediatric use of PDE-5 inhibitors for pulmonary hypertension
Source: Hypertension News From Medical News Today [2017.02.28]
A systematic review of the comparative effectiveness and safety of phosphodiesterase type 5 (PDE-5) inhibitors in pediatric patients with pulmonary hypertension published in Pediatrics demonstrates...
Late-onset hypertension may lower dementia risk, study finds
Source: Hypertension News From Medical News Today [2017.01.17]
For the first time, a study investigates the link between high blood pressure later in life and the risk of dementia and cognitive decline.
Published Studies Related to Clorpres (Clonidine / Chlorthalidone)
The treatment of obese hypertensive black women: a comparative study of chlorthalidone versus clonidine. [1992.05]
OBJECTIVE: We attempted to determine a valid pharmacological approach for the control of high blood pressure in obese hypertensive patients using two antihypertensive agents with different pharmacological actions... CONCLUSIONS: We conclude that a rational approach to the treatment of hypertension in obese black women includes diuretics, a first choice attempt that tries to address the hemodynamic alterations previously identified in those patients. Combining diuretics with an alpha-adrenergic agonist resulted in complete control of blood pressure in most of the hypertensive patients in our study. The lowest dose of each antihypertensive medication, especially when used in combination, was effective in a high percentage of patients. The use of this antihypertensive approach also helps to clarify which of the underlying pathophysiological mechanisms should be targeted when other currently available antihypertensive medications are used.
Efficacy and safety of two-year therapy with transdermal clonidine for essential hypertension. [1988.05]
We evaluated the safety and efficacy of transdermal clonidine (TC) in 23 patients with essential hypertension over a two-year period...